Private equity investment in physician practices has grown from $5.8 billion in 2019 to over $20 billion annually by 2025. Every specialty has been touched: dermatology and ophthalmology led the first wave, followed by orthopedics, gastroenterology, cardiology, urology, and now primary care and behavioral health. If you own a medical practice generating more than $1 million in revenue, you have almost certainly received an unsolicited acquisition inquiry.
The question is no longer whether private equity is interested in your practice. The question is whether you are financially prepared to maximize the value of what you have built, and whether you understand the deal mechanics well enough to evaluate an offer intelligently.
Understanding EBITDA Multiples by Specialty
Private equity values medical practices as a multiple of EBITDA, which stands for earnings before interest, taxes, depreciation, and amortization. EBITDA is a proxy for the cash flow the business generates before financing and accounting decisions. The multiple applied to your EBITDA determines your enterprise value, which is the headline number in any acquisition.
Primary care practices currently trade at 5x to 7x EBITDA. The lower multiples reflect thinner margins, higher dependence on Medicare and Medicaid reimbursement, and lower revenue per provider compared to specialty practices. A primary care group generating $800,000 in adjusted EBITDA would receive offers in the $4 million to $5.6 million range.
Medical specialties including gastroenterology, cardiology, and pulmonology typically command 7x to 9x EBITDA. These practices benefit from higher procedure volumes, ancillary revenue streams (in-office endoscopy, cardiac catheterization, infusion therapy), and more favorable payer mixes. A GI practice with $1.5 million in EBITDA might receive offers between $10.5 million and $13.5 million.
Surgical specialties such as orthopedics and urology trade at 8x to 10x EBITDA. The premium reflects high per-case revenue, the ability to capture facility fees through ambulatory surgery centers, and strong referral patterns that create durable revenue streams.
Dental and ophthalmology practices command the highest multiples in healthcare PE, typically 9x to 12x EBITDA. These specialties benefit from high patient volumes, significant cash-pay and elective revenue (cosmetic, LASIK, implants), lower regulatory burden compared to hospital-based specialties, and proven platform scalability. A dental group generating $2 million in EBITDA can realistically expect offers of $18 million to $24 million.
These multiples are not fixed. They are the starting point of a negotiation, and the specific characteristics of your practice can push your multiple significantly above or below the range for your specialty.
What Drives Multiples Higher
Understanding the variables that influence multiples gives you a roadmap for the 12 to 24 months before a sale. These are the factors PE firms evaluate when deciding whether your practice warrants a premium.
Payer mix is the single most important valuation driver. A practice where 70% or more of revenue comes from commercial insurance commands 40-60% higher multiples than a practice with the same EBITDA but heavy Medicare or Medicaid dependence. The reason is reimbursement risk. Medicare rates are set by CMS and can be cut unilaterally. Commercial rates are negotiated and contractual, providing more predictable revenue. A dermatology practice generating $1.2 million in EBITDA with 75% commercial payer mix might trade at 11x, while the same EBITDA with 60% Medicare exposure might trade at 8x. That payer mix difference is worth $3.6 million in enterprise value on the same earnings.
Revenue diversification beyond professional fees. Practices with ancillary revenue streams are more valuable because they demonstrate multiple growth vectors. In-office diagnostics, pharmacy or dispensing, clinical research, aesthetic services, pathology, or imaging each add revenue layers that are often higher-margin than professional fees. A GI practice with an in-office endoscopy suite generates $2,500-$4,000 per procedure in facility and professional fees combined, versus $300-$500 for an office visit. PE firms see ancillary revenue as scalable across their platform.
Provider depth and succession. A practice dependent on a single physician-owner is riskier than one with four or five providers sharing the patient panel. PE firms discount single-provider practices because the key-man risk is extreme. If you are a solo practitioner, adding an associate 18-24 months before a sale reduces concentration risk and demonstrates that the practice can generate revenue without you.
Growth trajectory matters more than current size. A practice growing revenue at 12-15% annually will command a higher multiple than a larger but flat practice. PE firms are buying future cash flows, not just current ones. If you can demonstrate three to five years of consistent growth in collections, new patients, and procedures, your multiple moves to the upper end of the range.
Clean, auditable financials. This sounds basic but eliminates more physician practices from premium valuations than any other factor. PE firms will conduct a quality-of-earnings analysis (discussed below) that scrutinizes every line of your financials. If your books are messy, if personal expenses are running through the practice, if revenue recognition is inconsistent, or if you cannot produce monthly financial statements going back three years, the buyer either walks away or discounts the offer significantly.
The Quality-of-Earnings Process
Every PE acquisition involves a quality-of-earnings (QoE) analysis, which is an independent financial examination performed by a third-party accounting firm hired by the buyer. The QoE is more rigorous than an audit in some respects because its purpose is to determine whether your reported EBITDA is sustainable and accurately represents the cash-generating capacity of the practice.
Here is what the QoE team will examine. They will recast your income statement by normalizing owner compensation. If you are paying yourself $150,000 in salary but an employed physician in your role would earn $350,000, the QoE adds $200,000 to expenses, reducing EBITDA. Conversely, if you are overpaying yourself at $500,000 when market compensation is $350,000, the QoE adds $150,000 back to EBITDA. The goal is to show what the practice earns after paying fair market compensation for all provider services.
One-time and non-recurring expenses are added back. If you spent $80,000 on a one-time EHR migration, $30,000 on a lawsuit settlement, or $50,000 on a buildout for a new operatory, those are addbacks to EBITDA because they are not ongoing expenses. Legitimate addbacks increase your adjusted EBITDA and therefore your valuation. Aggressive or poorly documented addbacks raise red flags and erode buyer confidence.
Revenue sustainability is examined over a trailing 24-month period. The QoE team will analyze revenue by payer, by provider, by service line, and by month. They are looking for concentration risk (is 40% of revenue coming from one payer contract that could be renegotiated?), seasonality patterns, declining trends in any segment, and whether recent revenue growth is organic or driven by one-time events.
Working capital is normalized. PE buyers expect to acquire the practice with a "normal" level of working capital, typically defined as the trailing twelve-month average of current assets minus current liabilities. If your accounts receivable are unusually high or low at closing, the purchase price is adjusted accordingly through a working capital true-up mechanism.
The QoE process typically takes six to eight weeks and involves extensive data requests. Practices that have organized financial records, clean chart of accounts, and an experienced bookkeeper or controller can navigate this efficiently. Practices that have been running on cash-basis QuickBooks with personal and business expenses commingled face a painful and expensive cleanup.
Preparing Your Financials: The 18-24 Month Runway
The physicians who maximize their sale price start preparing eighteen to twenty-four months before engaging with potential buyers. Here is the financial preparation timeline we recommend.
Months 18-24: Clean the books. Separate all personal expenses from the practice. Establish a proper chart of accounts with categories that a buyer will recognize. Transition to accrual-basis accounting if you are still on cash basis. Ensure all provider compensation is at fair market value and documented. Begin producing monthly financial statements with a proper close process.
Months 12-18: Optimize the P&L. Renegotiate your lowest-performing payer contracts. Identify and implement ancillary revenue opportunities that can demonstrate traction within twelve months. Reduce obvious cost inefficiencies that suppress EBITDA. Every dollar of sustainable EBITDA improvement at a 9x multiple is worth $9 in enterprise value. If you can reduce supply costs by $30,000 annually, that adds $270,000 to your sale price.
Months 6-12: Document everything. Create written documentation for all clinical workflows, billing processes, and operational procedures. Compile all payer contracts, lease agreements, equipment schedules, and employment agreements into a single data room. Buyers pay more for practices that are turnkey because integration risk is lower.
Months 1-6: Engage advisors and go to market. Retain a healthcare transaction advisor (investment banker) who specializes in physician practice sales. They will prepare a confidential information memorandum, identify and contact potential buyers, manage the bidding process, and negotiate deal terms. A good advisor adds 15-25% to the transaction value through competitive tension and deal expertise.
Deal Structure: What You Actually Receive
The headline multiple is only part of the equation. How the deal is structured determines what you take home and the economic terms you live with for the next three to five years.
Cash at close is typically 60-75% of enterprise value. On a $10 million deal, expect $6 million to $7.5 million in cash at closing. This is the certain portion of your consideration. It arrives via wire transfer on closing day, reduced by any transaction expenses, debt payoffs, and working capital adjustments.
Equity rollover represents 20-30% of the deal. The PE firm will require you to reinvest $2 million to $3 million of your proceeds back into the combined platform company. This rollover equity aligns your interests with the PE firm and gives you a stake in the platform's growth. The thesis is that when the PE firm sells the entire platform in five to seven years (the "second bite of the apple"), your equity roll will have appreciated significantly. In successful platforms, the second liquidity event can be worth 50-100% of the first, meaning your $2.5 million rollover could return $5 million or more.
Employment agreement for 3-5 years is standard. The PE firm is buying your patient relationships and clinical production. They need you to stay long enough to retain patients and integrate into the platform. Your compensation during this period is typically structured as a base salary plus productivity bonus (often based on wRVU targets or collections). The base salary is usually at or above fair market value for your specialty. Restrictive covenants (non-compete, non-solicitation) extend one to two years beyond the employment term and cover a geographic radius of ten to twenty miles.
Earnout provisions tie 5-15% of consideration to future performance. If EBITDA grows to specified targets over two to three years post-close, you receive additional payments. Earnouts are the riskiest portion of consideration because you no longer have full control over the practice's operations, expenses, or strategic direction. Negotiate earnout targets carefully, using achievable benchmarks based on historical performance rather than aspirational growth projections.
Red Flags That Kill Deals
Having advised physicians through both successful closings and failed transactions, certain patterns consistently derail deals.
Revenue decline in the trailing twelve months. If your collections dropped 5% or more in the year before going to market, buyers either walk away or demand significant price reductions. PE firms are buying growth. Even flat revenue is concerning. The worst time to sell is during a revenue downturn, no matter how compelling the explanation.
Provider turnover without replacement. Losing a provider who generated 25% of practice revenue six months before a sale is catastrophic for valuation. The buyer cannot value revenue that left with the departing physician. Retention of key providers through the sale process is critical. Some sellers offer retention bonuses to associates, payable only upon successful close of the transaction.
Undisclosed liabilities. Pending malpractice claims, compliance investigations, billing audits, or employment disputes that surface during due diligence destroy trust. Even if the issue is minor, the failure to disclose it upfront signals that other problems may be hidden. Disclose everything proactively in the initial confidential information memorandum.
Unreasonable seller expectations. A physician who insists on a 14x multiple for a primary care practice with flat revenue and 50% Medicare payer mix will never close a deal. Understanding market-realistic multiples before engaging buyers prevents wasted time and advisor fees.
Tax Implications of the Sale
How you structure the sale has significant tax consequences. In a stock sale, you typically receive capital gains treatment on the full purchase price (less your basis in the stock), taxed at 20% federal plus 3.8% net investment income tax for high earners, totaling 23.8%. State capital gains taxes add 0% to 13.3% depending on your state.
In an asset sale, which is what most PE buyers prefer because it allows them to step up the tax basis of acquired assets, the proceeds are allocated across asset categories. Goodwill and other intangible assets receive capital gains treatment. Tangible assets may be subject to depreciation recapture at ordinary income rates. The net tax rate on an asset sale is typically 2-5 percentage points higher than a pure stock sale because of the depreciation recapture component.
Installment sales can defer tax recognition over multiple years, which is valuable if a large earnout is part of the consideration. Opportunity zone investments can defer and potentially reduce capital gains taxes on the proceeds. Charitable strategies, including donor-advised funds and charitable remainder trusts, can shelter a portion of the gain for philanthropically inclined physicians.
The interaction between entity type and sale structure is critical. As discussed in our article on entity selection for physicians, S-Corps provide significant tax advantages in an asset sale compared to C-Corps. If your practice is currently a C-Corp and you are contemplating a sale within five years, discuss conversion strategies with your tax advisor immediately, keeping in mind the built-in gains tax rules for S-Corp conversions.
The Timeline from First Inquiry to Close
A typical physician practice PE transaction takes six to nine months from engagement to close. The first two months involve preparation, financial packaging, and identifying target buyers. Months two through four involve receiving and negotiating letters of intent. Months four through seven are consumed by due diligence, including the quality-of-earnings analysis, legal review, and employment agreement negotiations. Months seven through nine involve final negotiations, definitive agreement execution, and closing.
During this entire period, your practice must continue performing at or above historical levels. Any revenue dip during due diligence gives the buyer leverage to renegotiate terms. This is why having a strong operational team and documented processes is essential. You cannot spend six months focused on the transaction and expect the practice to run itself.
Getting Professional Help Before the Process Begins
The physicians who achieve the highest valuations are not the ones with the largest practices. They are the ones who prepare methodically, present clean financials, and enter the process with realistic expectations and experienced advisors.
A fractional CFO can serve as your financial quarterback throughout the preparation and transaction process. From cleaning up your chart of accounts and producing investor-grade financial statements, to modeling EBITDA adjustments, coordinating with your transaction advisor, and reviewing the quality-of-earnings findings, having experienced financial leadership ensures you do not leave money on the table or agree to terms you do not fully understand.
The time to start preparing is not when you receive an LOI. It is eighteen to twenty-four months before you want to close. Every month of preparation translates directly into dollars at the closing table.